23AndMe founder Anne Wojcicki will speak at the House Committee on Surveillance and Government Reform Jurisdictions held in Washington, DC on June 10, 2025.
Andrew Harnik | Getty Images
Anne Wojcicki, co-founder and former CEO of 23AndMe, has regained control of the genetic testing company she fought after Outbided by her new nonprofit, the TTAM Research Institute. Regeneron PharmaceuticalsThe company announced on Friday.
TTAM will acquire significant all of 23andMe’s assets for $305 million, including Lemonaid Health, a subsidiary of TeleHealth. It’s a big win for Wojcicki. Wojcicki resigned from his role as CEO when 23Andme filed for Chapter 11 bankruptcy protection in March.
Last month, Regeneron announced that it would buy most of the 23andme’s assets for $256 million after being on top during a bankruptcy auction. However, Wojcicki submitted separate $305 million bids through TTAM, pushing for the auction to resume. According to the Wall Street Journal, TTAM is the acronym for the first letter of 23andMe.
“We are excited to continue the 23andMe mission and help people access, understand and benefit from the human genome,” Wojcicki said in a statement.
23AndMe gained popularity as the home-based DNA test kit gave insight into family history and genetic profiles. The five CNBC Disruptor 50 Company was published in 2021 through a merger with a special purpose acquisition company. At its peak, 23andMe was valued at around $6 billion.
The company struggled to generate recurring revenues and create viable research and treatments after it was published. Since hackers accessed information from nearly 7 million customers in 2023, privacy concerns have been plagued by.
The acquisition of TTAM is subject to approval by the US Bankruptcy Court for the Eastern District of Missouri.
